>
GURUFOCUS.COM > STOCK LIST > Healthcare > Biotechnology > VistaGen Therapeutics Inc (NAS:VTGN) > Definitions > Cash Flow from Investing
Switch to:

VistaGen Therapeutics Cash Flow from Investing

: $-0.20 Mil (TTM As of Mar. 2022)
View and export this data going back to 2011. Start your Free Trial

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2022, VistaGen Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, VistaGen Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2022.


VistaGen Therapeutics Cash Flow from Investing Historical Data

The historical data trend for VistaGen Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Cash Flow from Investing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.17 - -0.28 -0.20

VistaGen Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Cash Flow from Investing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.15 -0.05 - -

VistaGen Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

VistaGen Therapeutics's Cash Flow from Investing for the fiscal year that ended in Mar. 2022 is calculated as:

VistaGen Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VistaGen Therapeutics  (NAS:VTGN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

VistaGen Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

VistaGen Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

VistaGen Therapeutics's purchase of business for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

VistaGen Therapeutics's sale of business for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

VistaGen Therapeutics's purchase of investment for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

VistaGen Therapeutics's sale of investment for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

VistaGen Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

VistaGen Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2022 was 0.00 Mil. It means VistaGen Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

VistaGen Therapeutics's cash from other investing activities for the three months ended in Mar. 2022 was $0.00 Mil. It means VistaGen Therapeutics paid $0.00 Mil for other investing activities.


VistaGen Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Saxe Jon S director FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane officer: VP, CFO AND SECRETARY 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph director, officer: PRES./CHIEF SCIENTIFIC OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A. officer: VP CORPORATE DEVELOPMENT C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin officer: VP CORPORATE DEVELOPMENT 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie director, 10 percent owner, officer: PRESIDENT 13834 W. HOYT ROAD RATHDRUM ID 83858

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)